Metsera, Inc.
MTSR evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Market Cap:
- $7.43B
- Lead Asset:
- met-097i (Phase 2)
What it means
What to watch
Prepared research question
What matters most for MTSR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$7.43B
Cash Runway
—
Lead Asset
met-097i (Phase 2)
Next Catalyst
—
Tracking 4 pipeline candidates for Metsera, Inc..
Run Metsera, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Metsera, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is Metsera, Inc.'s lead drug candidate?
Metsera, Inc.'s most advanced tracked candidate is met-097i (Phase 2) for obesity and overweight.
Who is the CEO of Metsera, Inc.?
Mr. Christopher Whitten Bernard is the chief executive officer of Metsera, Inc. (MTSR).
Where is Metsera, Inc. headquartered?
Metsera, Inc. (MTSR) is headquartered in New York, NY, United States.
What therapeutic areas does Metsera, Inc. focus on?
Metsera, Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.